Osteoprotegerin, a pivotal regulator of the osteoclastic activity, (Hofbauer and Schoppet, 2004) has been found to be increased in prostate cancer patients with bone metastases – but not in those with localised diseases (Brown et al, 2001; Jung et al, 2004). This evidence concerns the gene TNFRSF11B and prostate carcinoma.